Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study of DS-8500a in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged ≥ 20 years at the time of informed consent~* Japanese patients with type 2 diabetes~* Patients who have HbA1c ≥ 7.0% and \< 10.0% if untreated with antidiabetic agent.~* Patients who have HbA1c ≥ 6.5% and \< 9.5% if treated with antidiabetic agent.~Exclusion Criteria:~* Patients aged ≥ 70 years at the time of informed consent~* Patients with a history of type 1 diabetes or diabetic ketoacidosis~* Patients receiving or requiring treatment with insulin~* Patients with a body mass index (BMI) of \< 18.5 kg/m2 or ≥ 35.0 kg/m2~* Patients with an estimated glomerular filtration rate (eGFR), \< 45 mL/min per 1.73 m2~* Patients with fasting plasma glucose ≥ 240 mg/dL

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- DS-8500a 10mg once daily (Type: EXPERIMENTAL): 10mg DS-8500a tablet given orally once daily
- DS8500a 75 mg once daily (Type: EXPERIMENTAL): 75mg DS-8500a tablet given orally once daily
- placebo to match DS-8500a tablet (Type: PLACEBO_COMPARATOR): placebo matching DS-8500a tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).